论文部分内容阅读
分别采用ELISA和RIA对36例卵巢恶性肿瘤、34例妇科良性肿瘤患者及31例正常女性献血员血清可溶性白细胞介素-2受体（sIL－2R）和CA125水平进行检测。结果：术前卵巢恶性肿瘤患者血清SIL－2R和CA125水平均明显高于良性及正常对照组（P<0.01）。血清sIL－2R检测恶性肿瘤的敏感性为77．8％，特异性为76.5％。血清CA125的敏感性为83．3％，特异性为73．5％。其中，对卵巢上皮癌敏感性为90．4％。联合检测卵巢恶性肿瘤患者血清sIL－2R和CA125的敏感性为57．4％，特异性为94．7％。提示：术前单项血清sIL－2R或CA125不能作为诊断和筛选卵巢恶性肿瘤的依据，联合检测血清sIL－2R或CA125可明显提高特异性，降低假阳性率，有助于临床手术方式的制定和以后治疗成功的可能性。
Serum soluble interleukin-2 receptor (sIL-2R) and CA125 levels were detected by ELISA and RIA in 36 cases of ovarian cancer, 34 cases of benign gynecologic tumors and 31 cases of normal female. Results: The serum levels of SIL-2R and CA125 in preoperative ovarian cancer patients were significantly higher than those in benign and normal controls (P <0.01). Serum sIL-2R detection of malignant tumors was 77.8%, specificity was 76.5%. Serum CA125 sensitivity was 83.3% and specificity was 73.5%. Among them, the sensitivity of epithelial ovarian cancer was 90.4%. The combined detection of serum sIL-2R and CA125 in patients with ovarian cancer was 57.4% with a specificity of 94.7%. It is suggested that preoperative single serum sIL-2R or CA125 can not be used as a basis for diagnosis and screening of ovarian cancer. Combined detection of serum sIL-2R or CA125 can significantly improve the specificity and reduce the false positive rate, which is helpful for the development of clinical surgical methods and The possibility of success after treatment.